Viral vectors can pose challenges in terms of scale-up, purification, and quality control. Lonza has a long-standing history in the development, clinical and commercial manufacturing of viral vectors, including AAV and lentivirus. We have the technologies, platforms and experienced teams to optimize vector production, ensure purity and potency, and develop scalable manufacturing processes. Our expertise in analytical testing also ensures that your product meets the highest standards of quality. Our team of scientists regularly publishes and presents peer-reviewed papers addressing the key challenges of viral vector manufacturing at industry conferences such as ASGCT and ESGCT.

Developing your autologous cell therapy manufacturing

Our approach to developing and manufacturing your therapy from concept to commercialization and beyond

Our New Product Introduction (NPI) and Lifecycle program, maps out your entire journey to commercialization. It accounts for each key milestone with checkpoints, to ensure you meet all required quality standards as your autologous cell therapy progresses towards commercialization. The NPI program leverages our heritage and longstanding experience in establishing cGMP manufacturing standards. It combines both corporate and local quality standards customized for cell and gene therapies, to de-risk your journey to commercialization.

Learn more

NPI graphic



Our location

Houston – a home with room to grow

Our 300,000 square-feet dedicated cell and gene therapy facility in Houston, Texas is designed by experts in cell and gene therapy to address the key challenges in the manufacturing of these therapies and the critical product supply needs of our customers.

The world’s largest dedicated cell and gene therapies manufacturing facility at the time of opening in 2018, our Houston site is now approved for commercial manufacture.

The modular designed cleanroom can be custom built to fit our client process needs in the existing shell space with a cost-effective and time-efficient manner. Working side-by-side with our clients in the product development life-cycle, we can de-risk your path to commercialization together, from developing regulatory-compliant industrialized process to securing cGMP capacities to meet market demand.

Learn more

Cell and Gene
Related Insights

By joining Lonza, you will get to work with some of the world’s top experts in the space, while developing advanced therapies with a potentially life-saving outcome.

Behnam Ahmadian - Global Head of Process Development 
Behnam Ahmadian Baghbaderani

Global Head of Process Development